Back to resultsPharmacotherapy and Intensive Treatment - 2
Primary Purpose
Cocaine-Related Disorders, Substance-Related Disorders
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Carbamazepine
Sponsored by
About this trial
This is an interventional treatment trial for Cocaine-Related Disorders focused on measuring cocaine dependence
Eligibility Criteria
Please contact site for information.
Sites / Locations
- University of Kansas
Outcomes
Primary Outcome Measures
Severity addiction
Depression
Depression, anxiety
Secondary Outcome Measures
Full Information
NCT ID
NCT00000218
First Posted
September 20, 1999
Last Updated
January 11, 2017
Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
VA Office of Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT00000218
Brief Title
Pharmacotherapy and Intensive Treatment - 2
Official Title
Pharmacotherapy and Intensive Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
National Institute on Drug Abuse (NIDA)
Collaborators
VA Office of Research and Development
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cocaine-Related Disorders, Substance-Related Disorders
Keywords
cocaine dependence
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Enrollment
353 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Carbamazepine
Primary Outcome Measure Information:
Title
Severity addiction
Title
Depression
Title
Depression, anxiety
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Please contact site for information.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Haning, M.D.
Organizational Affiliation
University of Kansas
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kansas
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64128
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Pharmacotherapy and Intensive Treatment - 2
We'll reach out to this number within 24 hrs